 Gainers Revelation Biosciences, Inc. NASDAQ: REVB rose 149.3 to 1.56 in pre-market trading after jumping 27 on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis. 